证券代码：301130 证券简称：西点药业 公告编号：2026-009 吉林省西点药业科技发展股份有限公司 关于取得金融机构股票回购专项贷款承诺书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 4、贷款用途：回购已发行上市股票。 5、贷款承诺书自建设银行法定代表人或授权代理人签字并加盖建设银行公 章之日（即签发之日）起生效，有效期截至 2027 年 1 月 29 日。 三、其他说明 本次取得贷款承诺书可为公司本次回购股份提供融资支持，具体贷款事宜以 公司与贷款银行签订的授信协议/贷款合同为准。本次取得金融机构股票回购专 项贷款承诺书不代表公司对本次回购金额的承诺，具体回购金额以本次回购结束 时实际使用的资金为准。 一、回购股份方案的基本情况 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2026 年 1 月 22 日召开第八届董事会第十四次会议审议通过了《关于回购公司股份方案的 议案》，同意公司以自有资金和/或自筹资金以集中竞价交易方式回购公司已发 行的人民币普通股（A 股）股票，用于实施员工持股计划或股权激励，本次回购 股份方案经三分之二 ...

证券日报网讯 1月28日，西点药业发布公告称，公司于2026年1月22日召开第八届董事会第十四次会 议，审议通过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现金管理和委 托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和资金安全的前提下，使用额度不超 过人民币7，500万元的部分闲置募集资金（含超募资金）进行现金管理，公司及全资子公司在确保不影 响公司日常经营的前提下，使用额度不超过人民币2.5亿元的部分闲置自有资金进行现金管理和委托理 财，用于购买安全性高、流动性好、期限不超过12个月的短期投资理财产品。使用期限自董事会审议通 过之日起12个月内有效。在上述额度和期限内，资金可循环滚动使用。 （编辑 任世碧） ...

二、审批程序 证券代码：301130 证券简称：西点药业 公告编号：2026-008 吉林省西点药业科技发展股份有限公司 关于使用闲置募集资金进行现金管理的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 | | --- | | 假记载、误导性陈述或重大遗漏。 | 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2026 年 1 月 22 日召开第八届董事会第十四次会议，审议通过了《关于使用部分闲置募集 资金进行现金管理及使用部分闲置自有资金进行现金管理和委托理财的议案》， 同意公司在确保募集资金投资项目建设正常进行和资金安全的前提下，使用额度 不超过人民币 7,500 万元的部分闲置募集资金（含超募资金）进行现金管理，公 司及全资子公司在确保不影响公司日常经营的前提下，使用额度不超过人民币 2.5 亿元的部分闲置自有资金进行现金管理和委托理财，用于购买安全性高、流 动性好、期限不超过 12 个月的短期投资理财产品。使用期限自董事会审议通过 之日起 12 个月内有效。在上述额度和期限内，资金可循环滚动使用。具体内容 详见公司在巨潮资讯网上披露的《关于使用部分闲置募集资金进行 ...

Group 1 - The core point of the article is that West Point Pharmaceutical (301130) announced a share buyback plan, intending to repurchase shares worth between 25 million to 50 million yuan, with a maximum buyback price set at 42 yuan per share [1] Group 2 - The company aims to enhance shareholder value through this buyback initiative [1] - The buyback range indicates a strategic move to stabilize or increase the stock price amid market fluctuations [1] - The announcement reflects the company's confidence in its financial health and future prospects [1]

Group 1 - The core viewpoint of the news is that Xidian Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant reliance on financing and a slight decline in revenue and profit [1][2]. Group 2 - On January 22, Xidian Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 29.64 million yuan. The financing buy-in amount was 2.27 million yuan, while the financing repayment was 3.19 million yuan, resulting in a net financing buy of -0.92 million yuan [1]. - As of January 22, the total balance of margin trading for Xidian Pharmaceutical was 127 million yuan, accounting for 5.27% of its circulating market value, which is above the 80th percentile level over the past year [1]. - The company has not engaged in any short selling activities on January 22, with a short selling balance of 0.00 shares, indicating a high level of caution among investors [1]. - Xidian Pharmaceutical, established on March 21, 1990, specializes in the research, production, and sales of chemical pharmaceutical raw materials and formulations, with its main revenue sources being Risperidone orally disintegrating tablets (54.15%) and compound ferrous sulfate folic acid tablets (45.13%) [1]. - As of September 30, the number of shareholders for Xidian Pharmaceutical was 7,863, a decrease of 2.91% from the previous period, while the average circulating shares per person increased by 2.97% to 7,426 shares [2]. - For the period from January to September 2025, Xidian Pharmaceutical reported a revenue of 189 million yuan, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 33.15 million yuan, down 2.70% year-on-year [2]. - Since its A-share listing, Xidian Pharmaceutical has distributed a total of 63.34 million yuan in dividends, with 52.83 million yuan distributed over the past three years [2].

Policy Developments - The Ministry of Commerce and nine other departments issued an opinion to promote the high-quality development of the pharmaceutical retail industry, proposing 18 specific measures focused on improving pharmaceutical services and emergency supply guarantees [1] - The opinion emphasizes the development of smart regulation, including accurate collection and verification of drug traceability codes and uploading to a national medical insurance information platform [1] - A dynamic regulatory model based on risk levels and credit evaluations will be implemented, optimizing inspection frequencies for low-risk enterprises and exploring non-on-site supervision methods like AI video inspections [1] Drug Approval - Yuandong Bio's subsidiary Shod Pharmaceutical received a drug registration certificate for chloral hydrate syrup, aimed at sedation and hypnosis for children, marking the company's first approved Class 2 modified new drug [2] - West Point Pharmaceutical announced the approval of glucosamine sulfate capsules for primary or secondary osteoarthritis, enhancing its product line but facing sales uncertainties due to industry policies and procurement factors [3] Capital Market - OpenEvidence, a medical AI startup, completed a $250 million Series D financing round, achieving a valuation of $12 billion, with total financing nearing $700 million [4] - West Point Pharmaceutical plans to repurchase shares worth between 25 million and 50 million RMB, with a maximum repurchase price of 42.00 RMB per share, representing 0.78% to 1.56% of its total A-share capital [5] Industry Developments - Baichuan Intelligent launched the evidence-enhanced medical model M3 Plus, reducing hallucination rates to 2.6%, the lowest globally, and introduced the "evidence anchoring" technology to link generated medical conclusions to original research [6][7] - Sinovac's inactivated hepatitis A vaccine has secured a two-year exclusive bid in Oman, with over 130 million doses supplied globally, making it one of the most widely used hepatitis A vaccines [8] Public Opinion Alerts - Yiju Medical announced the resignation of non-executive director Dr. Zhou Yi, effective January 22, 2026, to focus on other business commitments [9]

Group 1: Company Fundraising and Investment - Company plans to use 500 million yuan of raised funds to increase capital in its wholly-owned subsidiaries for the implementation of a DRAM investment project [1] - Zhuhai Hengqin Chip Storage Co., Ltd. will receive 30 million yuan, and Hefei Chip Storage Co., Ltd. and Xi'an Chip Storage Co., Ltd. will receive 50 million yuan and 30 million yuan respectively for the DRAM project [1] Group 2: Profit Forecasts and Turnarounds - Yiling Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan in 2025, recovering from a loss of 725 million yuan in the previous year [2] - Liard anticipates a net profit of 300 million to 380 million yuan in 2025, compared to a loss of 889 million yuan last year, driven by a new strategic cycle focusing on AI [2] - Daming City forecasts a net profit of 140 million to 165 million yuan in 2025, recovering from a loss in the previous year, aided by reduced asset impairment losses [3] - Guanghua Technology expects a net profit of 85 million to 120 million yuan in 2025, recovering from a loss of 205 million yuan last year, due to expansion in specialized chemicals and PCB sectors [3] - Boteng Co. anticipates a net profit of 80 million to 105 million yuan in 2025, recovering from a loss of 288 million yuan, supported by operational efficiency improvements [4] - Shiyida expects a net profit of 31 million to 46 million yuan in 2025, recovering from a loss of 2.34 million yuan last year, driven by business development and cost control [4] - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan in 2025, recovering from a loss of 49 million yuan, aided by improved receivables management [5][6] Group 3: Share Buybacks - Hengyi Petrochemical plans to repurchase shares with a total fund of no less than 500 million yuan and no more than 1 billion yuan, with a maximum price of 15 yuan per share [7] - Yunyi Electric plans to repurchase shares with a total fund of no less than 100 million yuan and no more than 150 million yuan, with a maximum price of 17 yuan per share [7] - Xidian Pharmaceutical intends to repurchase shares with a total fund of no less than 25 million yuan and no more than 50 million yuan, with a maximum price of 42 yuan per share [7] Group 4: Performance Highlights - Te Yi Pharmaceutical expects a net profit of 70 million to 90 million yuan in 2025, a growth of 241.55% to 339.13% year-on-year [8] - Xingqi Eye Medicine anticipates a net profit of 662 million to 749 million yuan in 2025, a growth of 95.82% to 121.56% year-on-year [8] - Tianhe Co. forecasts a net profit of 41 million to 60 million yuan in 2025, a growth of 84.35% to 169.78% year-on-year [8] - Ruichuang Micro-Nano expects a net profit of approximately 1.1 billion yuan in 2025, a 93% increase year-on-year [9] - Zhongyuan Co. anticipates a net profit of 139 million to 158 million yuan in 2025, a growth of 80% to 105% year-on-year [9] Group 5: Important Corporate Developments - Aolaide has received acceptance for its application to issue securities on the Science and Technology Innovation Board [14] - *ST Songfa's subsidiary signed contracts for the construction of two VLCC super-large oil tankers, expected to positively impact future performance [15] - Chongda Technology's subsidiary signed an investment agreement for a 1 billion yuan IC packaging project in Jiangsu Province [15] - Yinglian Co. signed a strategic agreement with LG Chem to establish a joint laboratory for innovative materials in lithium battery applications [16]

Group 1 - Honghe Technology's main product, electronic-grade glass fiber cloth, is one of the basic materials for PCB [1] - *ST Bio has terminated the planning of a major asset restructuring [1] - Dongpeng Beverage plans to invest 1.1 billion yuan in the "Dongpeng Beverage Chengdu Production Base Project" [1] - AudioFly Storage has won the equipment procurement project for Jingdezhen Art Vocational University [1] - ShenNan Electric A expects a net profit growth of 584.66% to 721.59% year-on-year in 2025 [1] - Shuihui Supermarket plans to sell 28.095% of its stake in Yunjin Technology to Paihui Technology [1] - Hengyi Petrochemical intends to repurchase shares worth 500 million to 1 billion yuan [1] - Mongolian Grass Ecology's actual controller Wang Zhaoming plans to reduce his stake by no more than 2.3311% [1] - Jiangsu Yinglian Recycled Fluid has signed a "Joint Laboratory Strategic Agreement" with LG Chem [1] - Lizhong Group has received a fixed-point notification for an aluminum alloy wheel project from a client [1] Group 2 - Hengyi Petrochemical plans to repurchase shares worth 500 million to 1 billion yuan [2] - Yinglian shares' subsidiary has signed a "Joint Laboratory Strategic Agreement" with LG Chem [2] - Yunyi Electric plans to repurchase shares worth 100 million to 150 million yuan [2] - Xiduan Pharmaceutical intends to repurchase shares worth 25 million to 50 million yuan [2] - Junchen Technology's controlling partner plans to reduce its stake by no more than 2.94% [2] - Green Alliance Technology's cybersecurity fund plans to reduce its stake by no more than 3% [2] - Mongolian Grass Ecology's actual controller Wang Zhaoming plans to reduce his stake by no more than 2.3311% [2] - Yunyi Electric's chairman and general manager Fu Hongling plans to increase his stake by 30 million to 60 million yuan [2] - Lizhong Group has received a fixed-point notification for an aluminum alloy wheel project from a client [2]

Group 1 - The company, West Point Pharmaceutical, announced a plan to repurchase its issued A-shares using self-owned and/or self-raised funds through centralized bidding [2] - The total amount for the repurchase is set to be no less than RMB 25 million and no more than RMB 50 million [2] - The repurchase price will not exceed RMB 42.00 per share [2] - The implementation period for the repurchase is within 12 months from the date the board of directors approves the plan [2]

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]